​​​​​​​ HemOncTimes  

     Leukemia​           Lymphoma           Multiple Myeloma​

​​​Online Exclusive


Comprehensive CAR T-Cell Therapy Pediatric Guidelines Developed​

These guidelines outline lessons learned by experts in various fields to identify early signs and symptoms of treatment-related toxicity and detail ways to manage it.

Featured Articles

CML.jpegCombination Therapy Shows Synergistic Effect in Myeloma Treatment

By Yubin Kang, MD, & Pasupathi Sundaramoorthy, PhD

There is an unmet need for novel targeted therapies for multiple myeloma patients.​

CML.jpeg The Ibrutinib-Venetoclax Combination in Mantle Cell Lymphoma

By Richard Simoneaux

“Dual targeting of BTK and BCL2 with ibrutinib and venetoclax was consistent with improved outcomes in MCL patients.”

CML.jpeg Helping Patients Overcome Enrollment Barriers in Blood Cancer Trials

By Scott Kerwin, ​MN, RN, CCRC, CCRN

Despite extensive efforts to increase enrollment in cancer trials, there has been little success​. ​


New Therapies Target the Achilles Heels of Multiple Myeloma

By Mark L. Fuerst

New targets of the Achilles heels in myeloma have led to a handful of promising strategies for treatment.



Clinical Trials of Interest 

Pierluigi Porcu, MD, Director of the Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at the Sidney Kimmel Cancer Center at Jefferson Health, discusses a few hematology/oncology clinical trials in which he and his team are involved.​ WATCH NOW!​

Earn CME!

Evaluating CAR-T Therapy in Refractory B-Cell Lymphomas​​​​

The study and use of CAR T-cell therapy has expanded over the past year. One potential therapy for patients with B-cell lymphoma is axicabtagene ciloleucel, which utilizes the patient's own genetically modified T cells.​